furan-2-ylmethyl 2-methylprop-2-enoate | CAS:3454-28-2

We serve furan-2-ylmethyl 2-methylprop-2-enoate CAS:3454-28-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
furan-2-ylmethyl 2-methylprop-2-enoate

Chemical Name:furan-2-ylmethyl 2-methylprop-2-enoate
CAS.NO:3454-28-2
Synonyms:furan-2-ylmethyl 2-methylprop-2-enoate
Methacrylic acid,furfuryl ester
Furfuryl methacrylate
2-furylmethyl methacrylate
Methacrylsaeure-furfurylester
Furfuryl-methacrylat
Molecular Formula:C9H10O3
Molecular Weight:166.17400
 
Physical and Chemical Properties:
Density:1.078
Boiling point:60ºC
Flash point:195°F
Index of Refraction:1.482
 
Specification:
Appearance:Yellow transparent liquid
Assay:≥97.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:For synthetic resin monomers



Contact us for information like furan-2-ylmethyl 2-methylprop-2-enoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Furfuryl-methacrylat physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Furfuryl methacrylate Use and application,Furfuryl methacrylate technical grade,usp/ep/jp grade.


Related News: Such was the apparent demand sparked by the notice that the compound formula sold out on some stores on China’s e-commerce platform Taobao.2-(Chloro(4-chlorophenyl)methyl)pyridine manufacturer Since first being reported in the city of Wuhan, where it is believed to have originated at a seafood market, the virus has not provoked unusual symptoms in people who have been diagnosed.9-Bromo-7,7-dimethyl-7H-benzo[c]fluorene supplier It has reserves in the direction of APIs and intermediates for lowering blood lipids, lowering blood sugar and anticoagulation.phenyl N-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]carbamate vendor Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).How can I protect myself? Take the same precautionary measures you would during flu season. Wash your hands often with soap and water, cover your nose and mouth when you sneeze or cough, avoid close contact with people or large gatherings, and wear a face mask.